203 related articles for article (PubMed ID: 34380474)
21. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
23. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
Elliott JW
J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616
[TBL] [Abstract][Full Text] [Related]
24. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
Gustafson TL; Biller B
J Am Anim Hosp Assoc; 2019; 55(5):243-248. PubMed ID: 31433219
[No Abstract] [Full Text] [Related]
25. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
Yamazaki H; Tanaka T; Mie K; Nishida H; Miura N; Akiyoshi H
J Vet Intern Med; 2020 May; 34(3):1272-1281. PubMed ID: 32267594
[TBL] [Abstract][Full Text] [Related]
26. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
28. A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.
Rippy SB; Gardner HL; Nguyen SM; Warry EE; Portela RA; Drost WT; Hostnik ET; Green EM; Chew DJ; Peng J; London CA
BMC Vet Res; 2016 Nov; 12(1):257. PubMed ID: 27855679
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
Piscoya SL; Hume KR; Balkman CE
Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
[TBL] [Abstract][Full Text] [Related]
30. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
[TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
Laver T; London CA; Vail DM; Biller BJ; Coy J; Thamm DH
Vet Comp Oncol; 2018 Mar; 16(1):E23-E29. PubMed ID: 28621057
[TBL] [Abstract][Full Text] [Related]
32. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
[TBL] [Abstract][Full Text] [Related]
33. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
[TBL] [Abstract][Full Text] [Related]
34. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review.
Frezoulis P; Harper A
Vet Comp Oncol; 2022 Jun; 20(2):362-371. PubMed ID: 34981886
[TBL] [Abstract][Full Text] [Related]
35. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
[TBL] [Abstract][Full Text] [Related]
36. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
Rossi F; Sabattini S; Vascellari M; Marconato L
Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
[TBL] [Abstract][Full Text] [Related]
37. Assessment of tumor enhancement by contrast-enhanced CT in solid tumor-bearing dogs treated with toceranib phosphate.
Takagi S; Yamazaki H; Izumi Y; Hanazono K; Hoshino Y; Hosoya K
Vet Radiol Ultrasound; 2020 Jul; 61(4):427-434. PubMed ID: 32162400
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia).
Elliott JW; Swinbourne F; Parry A; Baines L
J Small Anim Pract; 2017 Jul; 58(7):416-418. PubMed ID: 28199021
[TBL] [Abstract][Full Text] [Related]
39. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
40. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.
Olmsted GA; Farrelly J; Post GS; Smith J
J Feline Med Surg; 2017 Jun; 19(6):568-575. PubMed ID: 26951557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]